There are many unmet needs in medical dermatology, especially in rare dermatologic diseases that may not have any approved therapies. In many of these cases, oral therapies that are often used off-label have demonstrated efficacy but may be associated with serious systemic toxicity, which then limits their viability as a treatment option.
Recent research has demonstrated that novel topical formulations of these drugs may represent safer treatment options that can lead to important clinically meaningful outcomes in many rare dermatologic diseases.
At Timber, our primary focus is on Congenital Ichthyosis
Congenital Ichthyosis (CI) is a group of rare genetic keratinization disorders that leads to dry, thickened, and scaling skin.
Most cases of ichthyosis are inherited, but some types develop in association with genetic syndromes or diseases, such as Hodgkin's Lymphoma.
People living with CI may have limited range of motion, chronic itching, an inability to sweat normally, high risk of secondary infections, and impaired eyesight or hearing. CI affects about 80,000 people in the U.S. and more than 1.5 million globally.